BioSpace News Archive

Vericel Corporation, a leader in advanced therapies for the sports medicine and severe burn care markets, reported financial results and business highlights for the second quarter ended June 30, 2021.

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an independent director.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), today announced the publication of three articles in peer-reviewed journals on pacmilimab (CX-072), the Company’s wholly-owned conditionally activated antibody directed against PD-L1 currently being developed in combination with praluzatamab ravtansine (CX-2009) for the treatment of triple-negative breast cancer (TNBC).

Neoleukin Therapeutics, Inc., today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual Canaccord Genuity 41 st Annual Growth Conference on Wednesday, August 11, 2021 at 8:00 a.m. Eastern Time.

Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

Kintara Therapeutics, Inc announced today that Saiid Zarrabian , Chief Executive Officer, will participate at the BTIG Virtual Biotechnology Conference on August 9, 2021 .

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the second quarter ended June 30, 2021, including the following operational and performance highlights.

Append Medical, developer of the first no-implant minimally invasive solution for transcatheter Left Atrial Appendage exclusion, announced the completion of a $7.4 million Series A financing round.

Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Wednesday, August 11, 2021, at 8:00 a.m. ET to review its second quarter 2021 financial results and provide an update on the company.

Catabasis Pharmaceuticals, Inc. today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10 th , 2021 at 8:35am ET.